|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| C |
CARDIOVASCULAR PRODUCTS |
| C1B |
ANTIARRHYTHMIC
An arrhythmia is any variation from the normal rhythm of the heart beat and includes sinus arrhythmia, heart block, atrial and ventricular fibrillation, ventricular tachycardia, and atrial flutter. Products under investigation include agents that act as Class I antiarrhythmics (sodium channel blockers), Class II (b -adrenergic blockers), Class III (prolong repolarization) and Class IV (calcium channel blockade). Other compounds include adenosine receptor agonists, inhibitors of the sodium/hydrogen ion pump and cardioglycosides. |
| C1C1 |
CARDIOSTIMULANT
Products in development for the treatment of heart failure (cardiac failure, congestive heart failure (CHF)) include positive inotropic agents, cardiac glycosides, cardioselective phosphodiesterase III and IV inhibitors. |
| C1D1 |
VASODILATOR, CORONARY
Coronary vasodilators are used for the treatment of coronary insufficiency, heart failure (see C1C1) and angina (see C1D3). Products include selective adenosine A2 receptor agonists, calcium antagonists and potassium channel activators. |
| C1D3 |
ANTIANGINAL
Antianginal treatment aims to restore the balance of myocardial oxygen supply and demand. Products under development for all types of angina include nitrates, calcium antagonists and b -blockers. The role of the GPIIb/IIIa receptor is also being investigated. |
| C2B1 |
ANTIHYPERTENSIVE, ADRENERGIC
The products in this category exert their antihypertensive activity through their action on the adrenergic system and include b -blockers, a -agonists/antagonists, mixed a +b -antagonists and adrenergic neurone blockers. |
| C2B2 |
ANTIHYPERTENSIVE, RENIN SYSTEM
The products in this category exert their antihypertensive activity through their action on the renin-angiotensin system and includes inhibitors of angiotensin converting enzyme (ACE) and renin and also angiotensin II antagonists. |
| C2B6 |
ANTIHYPERTENSIVE, DIURETIC
The products in this category exert their antihypertensive activity through their action on kidney function and include thiazide, potassium-sparing and loop diuretics, carbonic anhydrase inhibitors and anaritides. For uricosuric diuretics that are not used as antihypertensive agents, see antigout (M4A). |
| C2B9 |
ANTIHYPERTENSIVE, OTHER
The products in this category include calcium antagonists and vasodilators that are used as antihypertensives. Also included are antihypertensives with an unknown or not easily classified mode of antihypertensive action. |
| C4A |
VASODILATOR, PERIPHERAL
Peripheral vasodilators are mainly used in the treatment of hypertension in patients who are refractory to b -blockers and diuretics. They are also used in peripheral vascular disease, such as in Raynaud's syndrome. Vasodilators for hypertension or peripheral vascular disease include non-selective b -blockers and adenosine A1-antagonists. Other products include recombinant human calcitonin gene-related peptides and potassium channel activators. |
| C4B |
VASODILATOR, RENAL
Vasodilators that act by reducing renal vascular resistance are mainly used in hypertension, impaired renal function and renal calculi (stones) and those in development include dopamine prodrugs, recombinant a -human atrial natriuretic peptides and adenosine A2 antagonists. |
| C5A |
VASOPROTECTIVE, TOPICAL
Products for the topical treatment of the symptoms of chronic venous insufficiency and include antihaemorrhoidal and topical antivaricose preparations. |
| C5C |
VASOPROTECTIVE, SYSTEMIC
Products for the therapy of chronic venous insufficiency and post-thrombotic syndrome and those which reduce vascular permeability. Products under investigation include flavonoids with vasoprotective and healing promoting properties and potent free radical scavengers. |
| C6C |
HYPERTENSIVE
Products used in the treatment of hypotension include sympathomimetic agents which stimulate vascular a — and cardiac b -adrenoceptors and nitric oxide inhibitors for potential in interleukin-2-associated hypotension. |
| C9Z |
CARDIOVASCULAR
Products with cardiovascular activity which is either unknown to Pharmaprojects or not easily classified elsewhere. Products for myocardial infarction (whose mode of action cannot be classified elsewhere), systemic inflammatory response syndrome (SIRS) and cardiovascular shock (associated with trauma or burns). New agents for use in shock include monoclonal antibodies, PAF-antagonists and directly-acting a -adrenoceptor agonists. New compounds for use in myocardial infarction include selective 5-lipoxygenase inhibitors and inhibitors of membrane-bound phospholipase A2. |
| C10 |
HYPOLIPAEMIC/ANTIATHEROSCLEROSIS
Hyperlipoproteinaemias is when concentrations of triglycerides and cholesterol-carrying lipoproteins in the plasma are elevated. Products in development include HMG-CoA reductase inhibitors, acyl-CoA cholesterol transferase (ACAT) inhibitors, non-enzymatic glycosylation inhibitors and selective inhibitors of gastric lipase. |
top
| D |
DERMATOLOGICAL PRODUCTS |
| D3A |
VULNERARY
Vulneraries are agents which stimulate wound healing and are mainly used in the treatment of burns, scars, bedsores and other wounds which are difficult to heal. New compounds being investigated include fibroblast growth factor (FGF), recombinant granulocyte macrophage colony stimulating factor (GM-CSF), recombinant epidermal growth factor (EGF) and recombinant platelet-derived growth factor (PDGF). |
| D4A |
ANTIPRURITIC/INFLAMM, ALLERGIC
Topically and systemically administered compounds which relieve pruritus (itching) and inflammation caused by allergens, such as H1-receptor antagonists, topical steroids and monoclonal antibodies (MAbs) against immunoglobulin E (IgE), IgE and IgG. |
| D4B |
ANTIPRURITIC/INFLAMM, NON-ALLERGIC
Topically and systemically administered compounds which relieve non-allergic pruritus (itching) and inflammation, such as steroids and selective inhibitors of lipoxygenase enzymes. |
| D5A |
ANTIPSORIASIS
Psoriasis is a disease caused by non-malignant proliferation of epidermal cells. New products being developed include vitamin D analogues, topical steroids, lipoxygenase and cyclo-oxygenase inhibitors, leucotriene biosynthesis inhibitors, protein kinase C inhibitors and photodynamic agents. |
| D10A |
ANTIACNE
Products in development as antiacne agents include keratolytics, vitamin and retinoid derivatives and antibiotics. |
| D11Z |
DERMATOLOGICAL
Compounds with a dermatological action which is either unknown or cannot be classified in any of the other categories in the dermatology section. Products that are ablating agents for warts, hair growth promoters or used to specifically treat lupus erythematosus affecting the skin. New compounds under investigation antiandrogens and 5a -reductase inhibitors for alopecia and vitamin D analogues for cutaneous lupus erythematosus. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home